A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

Ormiston, John A.; Serruys, Patrick W.; Regar, Evelyn; Dudek, Dariusz; Thuesen, Leif; Webster, Mark; Onuma, Yoshinobu; García‐García, Héctor M.; McGreevy, Robert; Veldhof, Susan

doi:10.1016/s0140-6736(08)60415-8

Cited by 656 publications

(409 citation statements)

References 22 publications

Supporting

Mentioning

380

Contrasting

Unclassified

Order By: Relevance

“…The coverage of arterial wall by the expanded stent is similar to that of the conventional metallic stents (10%). 39 The radial strength at implantation is similar to that of stainless steel stents. 10 The stent is radiolucent.…”

Section: Biodegradable Magnesium Stentmentioning

confidence: 70%

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

2014

View full text Add to dashboard Cite

Since the advent of percutaneous coronary angioplasty in 1977, immense experiment has been done to improve the outcome of the patients with coronary artery disease. Lot of trials have been done with angioplasty, bare metal stents, drug eluting stents, drug eluting balloons and other devices. Bioabsorbable vascular stents are relatively newcomers in this field with a lot of hope. We tried to update the latest status of Bioabsorbable vascular stents in this review, specially the short and midterm safety and efficacy and some of their limitations. DOI: http://dx.doi.org/10.3329/cardio.v6i2.18359 Cardiovasc. j. 2014; 6(2): 149-163

show abstract

Section: Biodegradable Magnesium Stentmentioning

confidence: 70%

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

2014

View full text Add to dashboard Cite

show abstract

“…Both in-man and animal model studies described Absorb BVS 1.0 struts features during the different stages of the absorption process (41,42). Immediately after implantation, the polymeric struts are clearly identified.…”

Section: Optical Coherence Tomography (Oct)mentioning

confidence: 99%

Methods to assess bioresorbable vascular scaffold devices behaviour after implantation

et al. 2017

View full text Add to dashboard Cite

Bioresorbable vascular scaffolds (BRS) represent a novel approach for coronary revascularization offering several advantages as compared to current generation DES, potentially reducing rate of late adverse events and avoiding permanent vessel caging. Nevertheless, safety concerns have been raised for an increased risk of scaffold thrombosis (ScT) in both early and late phases, probably related to a suboptimal scaffold implantation. In this context, the use of different imaging methodologies has been strongly suggested in order to guarantee an optimal implantation. We herein analyze the different imaging methodologies available to assess BRS after implantation and at follow-up. J Thorac Dis 2017;9(Suppl 9):S959-S968 jtd.amegroups.com for BRS implantation in order to confirm optimal scaffold expansion, to exclude edge dissections, struts malapposition or underexpansion. Furthermore, imaging technique may evaluate at follow-up scaffold reabsorption and vessel changes over time. Keywords: Scaffold; intravascular ultrasound (IVUS); echogenicity; virtual histology-IVUS (VH-IVUS); optical coherence tomography (OCT); multislice coronary tomography (MSCT)SubmittedWe herein analyze the different imaging methodologies available to assess BRS after implantation and at follow-up. Quantitative coronary angiography (QCA)Coronary angiography is the most important method for assessing BRS implantation. As well as for conventional stent, at least two different projections with at least 30° difference for the right coronary artery and 3 different projections with at least 30° difference for the left coronary artery must be acquired before and after BRS implantation. The treated segment and the 5 mm proximal and distal to scaffold edges should be analyzed. As the bioresorbable devices are radiolucent, the QCA analysis may be performed visualizing the metallic markers of the scaffold.The following parameters can be measured. Acute recoilIt is defined as the difference between the mean diameter of the BRS delivery balloon (or, in case of post-dilatation, mean diameter of post-dilatation balloon) at the highest pressure and the mean lumen diameter (MLD) of the stented segment after balloon deflation. It can be expressed as absolute or relative value. The acute recoil is an important parameter in relation to the success of a PCI in acute and long-time period, as it has a direct impact on minimum stent area (MSA). A MSA less than 5.0 mm 2 is associated with high probability of in-stent restenosis (6).T h e a c u t e r e c o i l o f A b s o r b B V S 1 . 1 ( A b b o t t Laboratories, Abbott park, Illinois, USA) in the Absorb Cohort B trials and DESolve Nx BRS (Elixir Medical, Sunnyvale, California, USA) were 6.7%±6.4% and 6.4%±4.6%, respectively (7,8). These values are not dissimilar to those of metallic stent, showed in a Japanese study of 154 lesions comparing the biolimus eluting stent (Nobori stent, Terumo, Tokyo, Japan), cobalt chromium everolimus eluting stent (Xience V stent, Abbott Vascular, Santa Clara, CA, USA) and pl...

show abstract

“…In particular, we miss devices which can be delivered very distally or in very tortuous segments [24], dedicated bifurcation devices [25], and we still need to rely on permanent metallic platforms to ensure mechanical support and drug elution [26]. The Sparrow stent (Biosensors, Singapore, Singapore) is ideally posed to become a useful adjunct to the interventionist's armamentarium aiming to treat distal and tortuous lesions [27], whereas bioabsorbable endoprostheses (Absorb, Abbott Vascular) appear as very promising alternatives to standard metallic stents when permanency of the metallic platform is called into question [26]. Finally, drug-eluting balloons might become a routine means to revascularize patients with coronary artery disease as they may represent a suitable middle man between standard balloons and drug-eluting stents [28,29].…”

Section: Future Perspectivesmentioning

confidence: 99%

Drug-Eluting Stents in Interventional Cardiology

Biondi‐Zoccai¹

2012

Transl Med

View full text Add to dashboard Cite

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

Cited by 656 publications

References 22 publications

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

Bioabsorbable Vascular Scaffold: A Revolution in Coronary Intervention

Methods to assess bioresorbable vascular scaffold devices behaviour after implantation

Drug-Eluting Stents in Interventional Cardiology

Contact Info

Product

Resources

About